Israel’s Ministry of Health (MoH) approval to add additional sites to APEX SUMMIT-90 160 patient phase 2b macrodose clinical trial: Tel Aviv University (TAU)’s Institute for Psychedelic Research ...
Apex Labs CBD recently announced its entrance into a new frontier in delivery methods of cannabinoids—intravenous (IV) therapy—by pioneering a first-of-its-kind solution with patent-pending technology ...
VANCOUVER, BC, March 7, 2024 /CNW/ - Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the filing of ...
The investment aligns with SGC’s strategy of partnering with U.S.-based manufacturing businesses where operational excellence, disciplined execution, and strategic acquisitions can drive sustainable ...
Authorized to sell psilocybin through Health Canada's Special Access Program. "Receiving this licence is a significant achievement for APEX alongside our tremendous progress actively dosing patients ...
NEW ORLEANS, March 31, 2026 /PRNewswire/ -- LongueVue Capital ("LVC"), a New Orleans-based private equity firm, announced a strategic investment in Apex Dental Laboratory Group ("Apex" or the "Company ...
Swaney Group Capital (“SGC”), a Tampa-based private equity firm, in partnership with LongueVue Capital (“LVC”), a New Orleans-based private equity firm, announced a strategic investment in Apex Dental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results